The Five White-Collar Crime Myths, Along With an Explanation of the Reality Behind Them

DALLAS, TX / ACCESSWIRE / June 29, 2018 / “White-collar crime” is a phrase reportedly coined in 1939. It’s also a phrase that covers a wide range of criminal activities. To count as a white-collar crime, an offense must typically involve a financial or fraudulent activity that is non-violent. In many, but not all, cases, the individual who engages in a white-collar offense is someone in the business world. Also, many (but not all) white-collar crime defendants are people of means or people in a position of power or trust.

White-collar crime has become a favorite topic in Hollywood movies. As the success of award-winning film “The Wolf of Wall Street” shows, audiences are fascinated by tales of dramatic rises and falls from power. However, fictionalized accounts of white-collar crimes have led to a number of myths surrounding this area of criminal law. Here are five white-collar crime myths, along with an explanation of the reality behind them.

Myth #1: The Rich and Famous Don’t Get Prosecuted

Power often goes hand in hand with power, which leads some people to believe that the very wealthy and powerful are beyond the law. History shows that this simply isn’t true. In fact, some of the most infamous white-collar criminals were exceptionally powerful and wealthy people at the time they committed their crimes.

In recent years, prosecutors have pursued charges against a number of high-profile people in society. In the age of social media and the internet, fame isn’t necessarily a shield against prosecution. In fact, the ability of stories to “go viral” can often expose illegal acts to prosecution.

Myth #2: White-Collar Criminals Don’t Do Jail Time

Another persistent myth about white-collar crime assumes that people convicted of financial crimes rarely, if ever, serve lengthy prison sentences. A look at some of the most notorious white-collar crime cases reveal that this assertion is false. Several high-profile white-collar criminals have been sentenced to life in prison, while others have been sentenced to decades or even more than a century in prison. For people sentenced after midlife, this is essentially a life sentence.

Myth #3: “Ordinary” People Don’t Commit White-Collar Crimes

Because white-collar crimes involve money or financial issues like investments, many people assume that a person has to be wealthy to carry out this type of offense. The truth is many white-collar criminals are not people with large salaries or expensive homes. In fact, financial hardship is one of the main reasons why people engage in white-collar crime in the first place.

There have been a number of cases in which a sports coach or the head of a youth sports league mishandled funds meant for the league. Some of these individuals served jail time, while others were ordered to repay the money, serve probation, or carry out some other type of sentence.

Myth #4: White-Collar Crime Is Rare

It seems like the media covers a big white-collar crime story every few years — and then the public hears nothing else about white-collar crime after that. This sometimes leads people to believe that white collar-crime is quite rare.

In reality, white-collar crimes happen often. The media tends to only put a spotlight on cases that involve either a famous (or infamous) person or cases that involve a complicated and wide-ranging scheme. For example, the Bernie Madoff case involved dozens of celebrities as well as a massive amount of money. The idea of so many wealthy, famous people losing their life savings captivated audiences around the world. For this reason, the case received a great deal of attention.

However, there are plenty of white-collar crime prosecutions that never make the papers or television news. Smaller cases that involve unknown defendants or relatively smaller amounts of money may be a mere blip in the news cycle, if they register at all. Just because these cases are comparatively small, however, doesn’t mean they aren’t life-changing for the people involved.

Myth #5: White-Collar Criminals Are Treated Differently Than Violent Criminals

It’s common for people to assume that white-collar defendants receive more lenient sentences than individuals who carry out violent crimes. While it’s true that violent crimes, such as those carried out with a weapon or those that cause bodily injury or death, are subject to harsher penalties, white-collar crimes can also result in long prison sentences and costly fines.

Courts also consider a number of factors during the sentencing process, including how many people were hurt by the offense, as well as how much money was involved in the crime. For example, legal experts consider the Ponzi scheme perpetrated by Bernie Madoff to be the largest and most complex in history. Madoff carried out a fraud worth $64.8 billion, and the scheme harmed nearly 5,000 people. Madoff was sentenced to 150 years in prison.

CONTACT:

Broden & Mickelsen
Dallas Best Criminal Defense Lawyers
T: (214) 720-9552
https://www.brodenmickelsen.com/

Sources:

https://www.fbi.gov/investigate/white-collar-crime
https://www.biography.com/people/groups/white-collar-criminals
https://www.ohio.com/akron/news/local/former-medina-county-lacrosse-coach-repays-money-he-stole-from-league

***ATTORNEY ADVERTISING***

Prior results cannot and do not guarantee or predict a similar outcome with respect to any future case.

SOURCE: Broden and Mickelsen, LLP

ReleaseID: 503513

NEW YORK, NY / ACCESSWIRE / June 29, 2018 / It was a huge day for Gemphire Therapeutics on Thursday, skyrocketing over 120% in after-hours trading on the announcement that the company had achieved its primary endpoint in its Phase 2b INDIGO-1 trial in SHTG in patients with baseline serum TGs >500 mg/dL. Shares of Teva Pharmaceuticals saw gains after announcing that the company would be presenting new data for its migraine drug Fremanezumab at the AHS’s (American Headache Society) 60th Annual Scientific Meeting in San Francisco.

RDI Initiates Coverage on:

Teva Pharmaceutical Industries Ltd.
https://rdinvesting.com/news/?ticker=TEVA

Gemphire Therapeutics Inc.
https://rdinvesting.com/news/?ticker=GEMP

Teva Pharmaceutical Industries Limited shares closed up 4.53% yesterday on roughly 14.8 million shares traded. The Israeli-based pharma giant announced that it will present new data for its migraine drug Fremanezumab at the AHS’s (American Headache Society) 60th Annual Scientific Meeting in San Francisco. The drug is under review by the FDA for the preventive treatment of migraine in adults as a monthly or quarterly injection. The company said it intends to present 23 abstracts, three oral presentations, and one late-breaking poster of Fremanezumab. Tushar Shah, M.D., Senior Vice President, Head of Global Specialty Clinical Development at Teva commented, “Migraine remains a challenging disease with considerable unmet need, due to availability of few therapeutic innovations over the past 25 years. Teva is committed to developing novel treatments for patients with migraine headaches. We are excited to share additional data at the meeting on fremanezumab, particularly over the long-term, which is critical to patients.”

Access RDI’s Teva Pharmaceutical Industries Ltd. Research Report at:
https://rdinvesting.com/news/?ticker=TEVA

Gemphire Therapeutics Inc. shares closed down a little over 5% on Thursday but soared in after-hours trading with gains of over 120%. It was yesterday that the clinical-stage biopharmaceutical company announced that it achieved the primary endpoint, reduction of TGs by gemcabene, in its Phase 2b INDIGO-1 trial in SHTG patients with baseline serum TGs >500 mg/dL. Traders were celebrating as the results support the company’s rationale for developing gemcabene as a treatment for NAFLD/NASH.

Dr. Evan Stein, Director Emeritus, Metabolic & Atherosclerosis Research Center in Cincinnati, remarked, “The INDIGO-1 phase 2 study in severe hypertriglyceridemia clearly shows the 600 mg dose of gemcabene to be effective and well tolerated in this difficult to treat population. Importantly the triglyceride reduction is well supported by significant reductions in LDL-C, apoB, apoE, and apoCIII and these potentially beneficial reductions were greater in the subgroups that are even more difficult to treat, those with diabetes and already on statins.”

Dr. Lee Golden, Chief Medical Officer of Gemphire stated, “In a related note, we are pleased to report that both of our ongoing NAFLD/NASH proof-of-concept trials are dosing patients and remain on track to report data in late 2018 and early 2019 as previously guided. In addition, we are using the information from our INDIGO-1 trial, particularly the dose finding results, together with the results from our previous Phase 1 and 2 clinical trials, to finalize our Phase 3 trial plans. We expect to communicate more information regarding the structure and timing of our Phase 3 program once we have completed our End of Phase 2 meeting with the FDA, which we will request following the completion of the FDA’s review of the 2-year carcinogenicity study, which is currently in progress.”

Access RDI’s Gemphire Therapeutics Inc. Research Report at:
https://rdinvesting.com/news/?ticker=GEMP

Our Actionable Research on Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Gemphire Therapeutics Inc. (NASDAQ: GEMP) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 504131

NEW YORK, NY / ACCESSWIRE / June 29, 2018 / U.S. markets rebounded Thursday on the strength of the financial and technology sectors. The Dow Jones Industrial Average jumped 0.41 percent to close at 24,216.05, while the S&P 500 Index spiked 0.62 percent to close at 2,716.31. The Nasdaq Composite Index jumped 0.79 percent to close at 7,503.68. Shares of Bank of America, Citigroup, Goldman Sachs, J.P. Morgan and Morgan Stanley all posted gains of over 1 percent to lift the financial sector higher on Thursday.

“After 13 straight days of declines, financials finally bounced back. It’s good to see the leadership from this sector,” said Lindsey Bell, investment strategist at CFRA, according to MarketWatch. “Given the current environment when there lots of uncertainty surrounding global trade, investors continue to go to growth, such as technology shares and domestic stocks such as small-caps. Despite recent rotation, there has not been a real change in this sentiment,” Bell said.

RDI Initiates Coverage on:

Canopy Growth Corporation
https://rdinvesting.com/news/?ticker=CGC

GW Pharmaceuticals plc
https://rdinvesting.com/news/?ticker=GWPH

Canopy Growth’s stock jumped 10.97% Thursday, to close the day at $30.64. The stock recorded a trading volume of 7,307,063 shares, which was above its three months average volume of 1,882,870 shares. In the last year, Canopy Growth’s shares have traded in a range of 16.74 – 36.55. The share price has gained 83.03% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $29.16 is above its 200-day moving average of $25.49. Shares of Canopy Growth have gained roughly 13.90 percent in the past month and are up 18.26 percent year-to-date.

Access RDI’s Canopy Growth Corporation Research Report at:
https://rdinvesting.com/news/?ticker=CGC

On Thursday, shares of GW Pharmaceuticals recorded a trading volume of 758,610 shares, which was above the three months average volume of 454,395 shares. The stock ended the day 0.31% higher at $138.46. The share price has fallen 15.96% from its 52-week high with a 52-week trading range of 96.42 – 164.76. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $152.89 is above its 200-day moving average of $133.73. Shares of GW Pharmaceuticals have fallen roughly 14.05 percent in the past month and are up 4.89 percent year-to-date.

Access RDI’s GW Pharmaceuticals plc Research Report at:
https://rdinvesting.com/news/?ticker=GWPH

Our Actionable Research on Canopy Growth Corporation (NYSE:CGC) and GW Pharmaceuticals plc (NASDAQ:GWPH) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 504133

NEW YORK, NY / ACCESSWIRE / June 29, 2018 / U.S. markets rebounded Thursday on the strength of the financial and technology sectors. The Dow Jones Industrial Average jumped 0.41 percent to close at 24,216.05, while the S&P 500 Index spiked 0.62 percent to close at 2,716.31. The Nasdaq Composite Index jumped 0.79 percent to close at 7,503.68. Shares of Bank of America, Citigroup, Goldman Sachs, J.P. Morgan and Morgan Stanley all posted gains of over 1 percent to lift the financial sector higher on Thursday.

“After 13 straight days of declines, financials finally bounced back. It’s good to see the leadership from this sector,” said Lindsey Bell, investment strategist at CFRA, according to MarketWatch. “Given the current environment when there lots of uncertainty surrounding global trade, investors continue to go to growth, such as technology shares and domestic stocks such as small-caps. Despite recent rotation, there has not been a real change in this sentiment,” Bell said.

RDI Initiates Coverage on:

Celgene Corporation
https://rdinvesting.com/news/?ticker=CELG

Rite Aid Corporation
https://rdinvesting.com/news/?ticker=RAD

Celgene’s stock moved 0.76% lower Thursday, to close the day at $76.66. The stock recorded a trading volume of 5,813,223 shares, which was below its three months average volume of 6,771,126 shares. In the last year, Celgene’s shares have traded in a range of 74.13 – 147.17. The share price has gained 3.41% from its 52 week low. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $79.12 is below its 200-day moving average of $91.35. Shares of the company are trading at a Price to Earnings ratio of 21.42. Shares of Celgene have fallen roughly 2.51 percent in the past month and are down 26.54 percent year-to-date.

Access RDI’s Celgene Corporation Research Report at:
https://rdinvesting.com/news/?ticker=CELG

On Thursday, shares of Rite Aid recorded a trading volume of 31,458,416 shares, which was above the three months average volume of 13,176,148 shares. The stock ended the day 11.11% lower at $1.76. The share price has fallen 43.59% from its 52-week high with a 52-week trading range of 1.38 – 3.12. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $1.74 is below its 200-day moving average of $1.84. Shares of the company are trading at a Price to Earnings ratio of 1.96. Shares of Rite Aid have gained roughly 6.02 percent in the past month and are down 10.66 percent year-to-date.

Access RDI’s Rite Aid Corporation Research Report at:
https://rdinvesting.com/news/?ticker=RAD

Our Actionable Research on Celgene Corporation (NASDAQ:CELG) and Rite Aid Corporation (NYSE:RAD) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 504134

NEW YORK, NY / ACCESSWIRE / June 29, 2018 / U.S. markets rebounded Thursday on the strength of the financial and technology sectors. The Dow Jones Industrial Average jumped 0.41 percent to close at 24,216.05, while the S&P 500 Index spiked 0.62 percent to close at 2,716.31. The Nasdaq Composite Index jumped 0.79 percent to close at 7,503.68. Shares of Bank of America, Citigroup, Goldman Sachs, J.P. Morgan and Morgan Stanley all posted gains of over 1 percent to lift the financial sector higher on Thursday.

“After 13 straight days of declines, financials finally bounced back. It’s good to see the leadership from this sector,” said Lindsey Bell, investment strategist at CFRA, according to MarketWatch. “Given the current environment when there lots of uncertainty surrounding global trade, investors continue to go to growth, such as technology shares and domestic stocks such as small-caps. Despite recent rotation, there has not been a real change in this sentiment,” Bell said.

RDI Initiates Coverage on:

Dropbox, Inc.
https://rdinvesting.com/news/?ticker=DBX

Finisar Corporation
https://rdinvesting.com/news/?ticker=FNSR

Dropbox’s stock jumped 6.98% Thursday, to close the day at $33.40. The stock recorded a trading volume of 5,663,420 shares, which was above its three months average volume of 4,280,670 shares. In the last year, Dropbox’s shares have traded in a range of 27.75 – 43.50. The share price has gained 20.36% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $32.04 is above its 200-day moving average of $31.15. Shares of Dropbox have gained roughly 11.44 percent in the past month and are up 17.28 percent year-to-date.

Access RDI’s Dropbox, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=DBX

On Thursday, shares of Finisar recorded a trading volume of 3,712,742 shares, which was above the three months average volume of 2,872,448 shares. The stock ended the day 5.85% higher at $17.72. The share price has fallen 38.56% from its 52-week high with a 52-week trading range of 14.25 – 28.84. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $17.15 is below its 200-day moving average of $18.06. Shares of Finisar have gained roughly 4.11 percent in the past month and are down 12.92 percent year-to-date.

Access RDI’s Finisar Corporation Research Report at:
https://rdinvesting.com/news/?ticker=FNSR

Our Actionable Research on Dropbox, Inc. (NASDAQ:DBX) and Finisar Corporation (NASDAQ:FNSR) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 504136

NEW YORK, NY / ACCESSWIRE / June 29, 2018 / U.S. markets rebounded Thursday on the strength of the financial and technology sectors. The Dow Jones Industrial Average jumped 0.41 percent to close at 24,216.05, while the S&P 500 Index spiked 0.62 percent to close at 2,716.31. The Nasdaq Composite Index jumped 0.79 percent to close at 7,503.68. Shares of Bank of America, Citigroup, Goldman Sachs, J.P. Morgan and Morgan Stanley all posted gains of over 1 percent to lift the financial sector higher on Thursday.

“After 13 straight days of declines, financials finally bounced back. It’s good to see the leadership from this sector,” said Lindsey Bell, investment strategist at CFRA, according to MarketWatch. “Given the current environment when there lots of uncertainty surrounding global trade, investors continue to go to growth, such as technology shares and domestic stocks such as small-caps. Despite recent rotation, there has not been a real change in this sentiment,” Bell said.

RDI Initiates Coverage on:

Endo International plc
https://rdinvesting.com/news/?ticker=ENDP

Sangamo Therapeutics, Inc.
https://rdinvesting.com/news/?ticker=SGMO

Endo International’s stock jumped 7.9% Thursday, to close the day at $9.83. The stock recorded a trading volume of 7,082,650 shares, which was above its three months average volume of 6,328,304 shares. In the last year, Endo International’s shares have traded in a range of 5.27 – 12.54. The share price has gained 86.53% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $7.39 is above its 200-day moving average of $6.92. Shares of Endo International have gained roughly 55.78 percent in the past month and are up 26.84 percent year-to-date.

Access RDI’s Endo International plc Research Report at:
https://rdinvesting.com/news/?ticker=ENDP

On Thursday, shares of Sangamo Therapeutics recorded a trading volume of 2,703,330 shares, which was above the three months average volume of 2,564,440 shares. The stock ended the day 0.71% lower at $13.90. The share price has fallen 49.45% from its 52-week high with a 52-week trading range of 8.00 – 27.50. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $15.91 is below its 200-day moving average of $18.75. Shares of Sangamo Therapeutics have fallen roughly 10.90 percent in the past month and are down 15.24 percent year-to-date.

Access RDI’s Sangamo Therapeutics, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=SGMO

Our Actionable Research on Endo International plc (NASDAQ:ENDP) and Sangamo Therapeutics, Inc. (NASDAQ:SGMO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 504137

NEW YORK, NY / ACCESSWIRE / June 29, 2018 / U.S. markets rebounded Thursday on the strength of the financial and technology sectors. The Dow Jones Industrial Average jumped 0.41 percent to close at 24,216.05, while the S&P 500 Index spiked 0.62 percent to close at 2,716.31. The Nasdaq Composite Index jumped 0.79 percent to close at 7,503.68. Shares of Bank of America, Citigroup, Goldman Sachs, J.P. Morgan and Morgan Stanley all posted gains of over 1 percent to lift the financial sector higher on Thursday.

“After 13 straight days of declines, financials finally bounced back. It’s good to see the leadership from this sector,” said Lindsey Bell, investment strategist at CFRA, according to MarketWatch. “Given the current environment when there lots of uncertainty surrounding global trade, investors continue to go to growth, such as technology shares and domestic stocks such as small-caps. Despite recent rotation, there has not been a real change in this sentiment,” Bell said.

RDI Initiates Coverage on:

Activision Blizzard, Inc.
https://rdinvesting.com/news/?ticker=ATVI

Take-Two Interactive Software, Inc.
https://rdinvesting.com/news/?ticker=TTWO

Activision Blizzard’s stock jumped 3.53% Thursday, to close the day at $76.01. The stock recorded a trading volume of 4,318,008 shares, which was below its three months average volume of 5,650,757 shares. In the last year, Activision Blizzard’s shares have traded in a range of 55.86 – 79.63. The share price has gained 36.07% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $73.50 is above its 200-day moving average of $69.97. Shares of the company are trading at a Price to Earnings ratio of 166.69. Shares of Activision Blizzard have gained roughly 6.37 percent in the past month and are up 20.04 percent year-to-date.

Access RDI’s Activision Blizzard, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ATVI

On Thursday, shares of Take-Two Interactive Software recorded a trading volume of 2,090,559 shares, which was below the three months average volume of 2,201,473 shares. The stock ended the day 3.6% higher at $118.06. The share price has fallen 8.66% from its 52-week high with a 52-week trading range of 71.30 – 129.25. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $115.04 is above its 200-day moving average of $110.14. Shares of the company are trading at a Price to Earnings ratio of 76.76. Shares of Take-Two Interactive Software have gained roughly 5.39 percent in the past month and are up 7.54 percent year-to-date.

Access RDI’s Take-Two Interactive Software, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=TTWO

Our Actionable Research on Activision Blizzard, Inc. (NASDAQ:ATVI) and Take-Two Interactive Software, Inc. (NASDAQ:TTWO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 504138